Tyagi, Rajeev K and Jacobse, Justin and Li, Jing and Allaman, Margret M. and Otipoby, Kevin L. and Sampson, Erik R. and Wilson, K T and Goettel, Jeremy A. (2021) HLA-Restriction of Human Treg Cells Is Not Required for Therapeutic Efficacy of Low-Dose IL-2 in Humanized Mice. Frontiers in immunology, 12. ISSN 1664-3224
Full text not available from this repository. (Request a copy)Abstract
Regulatory T (T-reg) cells are essential to maintain immune homeostasis in the intestine and T-reg cell dysfunction is associated with several inflammatory and autoimmune disorders including inflammatory bowel disease (IBD). Efforts using low-dose (LD) interleukin-2 (IL-2) to expand autologous T-reg cells show therapeutic efficacy for several inflammatory conditions. Whether LD IL-2 is an effective strategy for treating patients with IBD is unknown. Recently, we demonstrated that LD IL-2 was protective against experimental colitis in immune humanized mice in which human CD4(+) T cells were restricted to human leukocyte antigen (HLA). Whether HLA restriction is required for human T-reg cells to ameliorate colitis following LD IL-2 therapy has not been demonstrated. Here, we show that treatment with LD IL-2 reduced 2,4,6-trinitrobenzensulfonic acid (TNBS) colitis severity in NOD.Prkdc(scid)Il2rg(-/-) (NSG) mice reconstituted with human CD34(+) hematopoietic stem cells. These data demonstrate the utility of standard immune humanized NSG mice as a pre-clinical model system to evaluate therapeutics targeting human T-reg cells to treat IBD.
| Item Type: | Article |
|---|---|
| Additional Information: | Open Access |
| Uncontrolled Keywords: | IBD; IL-2; Tregs; colitis; humanized. |
| Subjects: | Q Science > QR Microbiology > QR180 Immunology |
| Depositing User: | Dr. K.P.S.Sengar |
| Date Deposited: | 26 Mar 2021 04:19 |
| Last Modified: | 26 Mar 2021 04:19 |
| URI: | http://crdd.osdd.net/open/id/eprint/2660 |
Actions (login required)
 |
View Item |
